Alpha Tau Medical
DRTS
Market cap $157M

2.25 USD

-0.05

2.17%

At close Oct 18, 4:00 PM EDT

1 day

-2.17%

5 days

2.27%

1 month

-3.43%

3 months

5.63%

6 months

-15.41%

Year to date

-25.00%

1 year

-37.15%

5 years

-81.11%

About: Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.

Employees: 121

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

1.21% less ownership

Funds ownership: 3.07% [Q1] → 1.86% (-1.21%) [Q2]

11% less funds holding

Funds holding: 27 [Q1] → 24 (-3) [Q2]

48% less capital invested

Capital invested by funds: $6.26M [Q1] → $3.25M (-$3.01M) [Q2]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

211%

upside

Avg. target

$8.33

270%

upside

High target

$9

300%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen 35% 1-year accuracy 46 / 130 met price target	300%upside $9	Buy Reiterated	11 Oct 2024
HC Wainwright & Co. Yi Chen 35% 1-year accuracy 46 / 130 met price target	300%upside $9	Buy Reiterated	20 Aug 2024
Piper Sandler Jason Bednar 53% 1-year accuracy 23 / 43 met price target	211%upside $7	Overweight Reiterated	15 Aug 2024

See Analyst Rankings

Financial journalist opinion

Alpha Tau Treats First Patient with Recurrent Lung Cancer

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population -

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024.

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an overall response rate of almost 100% in treated le sions , no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $ 74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported second quarter 2024 financial results and provided a corporate update.

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau to Present at the Jefferies Global Healthcare Conference

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024.

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow -

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada.

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024.

Alpha Tau to Participate in May Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™